Studi In Silico Senyawa Turunan Kumarin sebagai Inhibitor Janus Kinase 1 (JAK1) pada Penyakit Rheumatoid Arthritis In Silico Study of Coumarin Derivative Compounds as Janus Kinase 1 (JAK1) Inhibitors in Rheumatoid Arthritis
Article Sidebar
Page Numbers:
1098-1109
Digital Object Identifier:
10.58578/masaliq.v6i3.9743
Viewed: 58 times
Downloaded: 55 times
LYAS Publisher cordially invites qualified professionals to serve as Editors or Reviewers. Your expertise will make an important contribution to maintaining and strengthening the academic quality of our publications. Interested applicants are kindly requested to complete the application form at the following link: Editors & Reviewers
Please feel free to contact us if you need any further information about the submission process or if you have any additional questions.
Authors:
Nur Aini Tsuraya1, Okta Suryani2* 
Copyright :
Authors retain copyright and grant the journal right of first publication.
Main Article Content
Abstract
Rheumatoid arthritis is a chronic autoimmune disease involving activation of the Janus kinase 1 (JAK1) pathway, making JAK1 a potential target in drug development. This study aims to evaluate the potential of coumarin derivative compounds as JAK1 inhibitors in silico. This study used a computational approach through the molecular docking method to predict ligand–protein interactions, evaluation of physicochemical properties based on Lipinski’s Rule of Five, and ADMET analysis to assess pharmacokinetic and toxicity profiles. The results show that all compounds had negative binding affinity values, ranging from -6.5379 to -6.9271 kcal/mol, indicating stable ligand–protein interactions, although these values were still lower than the positive control Tofacitinib, with a value of -7.3968 kcal/mol. All compounds met the criteria of Lipinski’s Rule of Five, but ADMET analysis showed variations in pharmacokinetic and toxicity profiles. Compound 3 showed the best balance between activity, stability, and safety, whereas compounds 1 and 2 showed potential mutagenicity. The conclusion of this study emphasizes that compound 3 has the potential to be further developed as a JAK1 inhibitor candidate. The implications of this study indicate the importance of structural optimization and further experimental validation to improve the effectiveness and safety of coumarin derivative compounds as therapeutic candidates for rheumatoid arthritis.
Downloads
Article Details
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
References
Alghamdi, A., Abouzied, A. S., Alamri, A., Anwar, S., Ansari, M., Khadra, I., Zaki, Y. H., & Gomha, S. M. (2023). Synthesis, molecular docking, and dynamic simulation targeting main protease (Mpro) of new, thiazole clubbed pyridine scaffolds as potential COVID-19 inhibitors. Current Issues in Molecular Biology, 45(2), 1422–1442. https://doi.org/10.3390/cimb45020093
Brown, P., Pratt, A. G., & Hyrich, K. L. (2024). Therapeutic advances in rheumatoid arthritis. BMJ, 384, e070856. https://doi.org/10.1136/bmj-2022-070856
Cacciapaglia, F., Perniola, S., Stano, S., Venerito, V., Natuzzi, D., Bizzoca, R., & Iannone, F. (2025). Modulation of IL-6 receptor/STAT3 downstream signaling in rheumatoid arthritis patients. Experimental and Molecular Pathology, 141, 104951. https://doi.org/10.1016/j.yexmp.2024.104951
Daina, A., Michielin, O., & Zoete, V. (2017). SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific Reports, 7, Article 42717. https://doi.org/10.1038/srep42717
Ferreira, L. L. G., & Andricopulo, A. D. (2019). ADMET modeling approaches in drug discovery. Drug Discovery Today, 24(5), 1157–1165. https://doi.org/10.1016/j.drudis.2019.03.015
Figueroa-Valverde, L., López-Ramos, M., Alvarez-Ramirez, M., Rosas Nexticapa, M., Díaz-Cedillo, F., Mateu-Armad, M. V., & Lopez-Gutierrez, T. (2023). Evaluation of coumarin and their derivatives as Janus Kinase-3 inhibitors using a theoretical model. Brazilian Journal of Science, 2(12), 106–117. https://doi.org/10.14295/bjs.v2i12.423
Furuhama, A., Sugiyama, K., & Honma, M. (2025). Ames mutagenicity of 15 aryl, benzyl, and aliphatic ring N-nitrosamines. Regulatory Toxicology and Pharmacology, 156, 105763. https://doi.org/10.1016/j.yrtph.2024.105763
Gadaleta, D., Vuković, K., Toma, C., Lavado, G. J., Karmaus, A. L., Mansouri, K., Kleinstreuer, N. C., Benfenati, E., & Roncaglioni, A. (2019). SAR and QSAR modeling of a large collection of LD50 rat acute oral toxicity data. Journal of Cheminformatics, 11, Article 58. https://doi.org/10.1186/s13321-019-0383-2
Holt, K., Nagar, S., & Korzekwa, K. (2019). Methods to predict volume of distribution. Current Pharmacology Reports, 5(5), 391–399. https://doi.org/10.1007/s40495-019-00186-5
Hosack, T., Damry, D., & Biswas, S. (2023). Drug-induced liver injury: A comprehensive review. Therapeutic Advances in Gastroenterology, 16, 17562848231163410. https://doi.org/10.1177/17562848231163410
Kaneshiro, K., Sakai, Y., Suzuki, K., Uchida, K., Tateishi, K., Terashima, Y., Kawasaki, Y., Shibanuma, N., Yoshida, K., & Hashiramoto, A. (2019). Interleukin-6 and tumour necrosis factor-α cooperatively promote cell cycle regulators and proliferate rheumatoid arthritis fibroblast-like synovial cells. Scandinavian Journal of Rheumatology, 48(5), 353–361. https://doi.org/10.1080/03009742.2019.1602164
Keretsu, S., Bhujbal, S. P., & Cho, S. J. (2021). Molecular modeling studies of pyrrolo[2,3-d]pyrimidin-4-amine derivatives as JAK1 inhibitors based on 3D-QSAR, molecular docking, molecular dynamics (MD) and MM-PBSA calculations. Journal of Biomolecular Structure and Dynamics, 39(3), 753–765. https://doi.org/10.1080/07391102.2020.1714483
Korzekwa, K., & Nagar, S. (2023). Process and system clearances in pharmacokinetic models: Our basic clearance concepts are correct. Drug Metabolism and Disposition, 51(4), 532–542. https://doi.org/10.1124/dmd.122.001060
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2012). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 64, 4–17. https://doi.org/10.1016/j.addr.2012.09.019
Mora Lagares, L., Minovski, N., & Novič, M. (2019). Multiclass classifier for P-glycoprotein substrates, inhibitors, and non-active compounds. Molecules, 24(10), Article 2006. https://doi.org/10.3390/molecules24102006
Panigrahi, D., & Sahu, S. K. (2025). Computational approaches: Atom-based 3D-QSAR, molecular docking, ADME-Tox, MD simulation and DFT to find novel multi-targeted anti-tubercular agents. BMC Chemistry, 19, Article 39. https://doi.org/10.1186/s13065-024-01357-2
Rahmani, B., Akbari, H., Esmaeili, H., Solaimanian, S., Mobasheri, M., & Shiri-Shahsavar, M. R. (2025). Discovering bioactive pharmaceuticals from natural products for type 2 diabetes mellitus using network pharmacology, molecular docking, and molecular dynamics. Scientific Reports, 15, Article 43205. https://doi.org/10.1038/s41598-025-27173-9
Ramírez, D., & Caballero, J. (2018). Is it reliable to take the molecular docking top scoring position as the best solution without considering available structural data? Molecules, 23(5), Article 1038. https://doi.org/10.3390/molecules23051038
Sandhiutami, N. M. D., Moordiani, M., Laksmitawati, D. R., Fauziah, N., Maesaroh, M., & Widowati, W. (2017). In vitro assesment of anti-inflammatory activities of coumarin and Indonesian cassia extract in RAW264.7 murine macrophage cell line. Iranian Journal of Basic Medical Sciences, 20(1), 99–106. https://doi.org/10.22038/ijbms.2017.8102
Zhao, M., Ma, J., Li, M., Zhang, Y., Jiang, B., Zhao, X., Huai, C., Shen, L., Zhang, N., He, L., & Qin, S. (2021). Cytochrome P450 enzymes and drug metabolism in humans. International Journal of Molecular Sciences, 22(23), Article 12808. https://doi.org/10.3390/ijms222312808